Nucl Med Mol Imaging.  2014 Sep;48(3):187-195. 10.1007/s13139-014-0280-6.

Prognostic Value of Metabolic Tumor Volume Estimated by 18F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease

Affiliations
  • 1Department of Nuclear Medicine, Gachon University Gil Medical Center, Gachon Univsersity School of Medicine, 21 Namdongdae-ro 774-gil, Namdong-gu, Incheon 405-760, Republic of Korea. d970012@hanmail.net
  • 2Department of Internal Medicine, Gachon University Gil Medical Center, Gachon Univsersity School of Medicine, 21 Namdongdae-ro 774-gil, Namdong-gu, Incheon 405-760, Republic of Korea. alertjun@hanmail.net

Abstract

PURPOSE
The purpose of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-containing immunochemotherapy.
METHODS
Patients with newly diagnosed DLBCL who underwent pre-treatment torso FDG-PET/CT scan taken within 10 days before treatment were included. MTV was defined as the volume of hypermetabolic tissue with a standardized uptake value (SUV) greater than a threshold value of 2.5 and calculated using volume viewer software. Association of MTV with patient characteristics and survival were compared.
RESULTS
A total of 96 patients were evaluated. During a median follow-up period of 27.8months, 3-year event-free survival (EFS) and overall survival was 69.5 % and 72.9 %, respectively. The Ann Arbor staging showed a limitation of prognosis because there was no difference of EFS between patients with Ann Arbor stage II and those with stage III. On the contrary, among patients with Ann Arbor stage II or III disease (n=53), the higher MTV group showed significantly inferior EFS compared with the lower MTV group.
CONCLUSIONS
In the current study, we identified the pretreatment MTV measured by FDG-PET/CT as a potential predictor of survival in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), at least in Ann Arbor stage II and III disease.

Keyword

Diffuse large cell lymphoma; Metabolic tumor volume; Tumor burden; Prognosis; Positron-emission tomography
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr